STOCK TITAN

Innovotech Reports Third Quarter 2026 Results

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Innovotech (IOTCF) reported a third-quarter 2026 net loss of C$390,335, narrowing 40% from the second quarter as costs declined. Revenue held steady at C$661,762, and loss per share was C$0.01. Gross margin rose to 29.8% from 8.6% in the second quarter. Total costs before grants and tax credits fell 22% sequentially to C$1.11 million; general and administrative expenses declined 24% to C$413,276.

Regulated testing services revenue reached C$363,112, up 9% year over year and 13% sequentially. Working capital was C$712,523 at September 30, and the current ratio improved to 2.28 from 2.07 at June 30. On October 29, Innovotech accepted an ATB Financial commitment for a C$500,000 revolving operating facility and a C$100,000 corporate credit card facility. The company expects its reduced cost base to be more fully reflected in the fourth quarter and remains focused on returning to profitability.

Loading...
Loading translation...
11 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointThird-quarter net loss narrowed 40% sequentially to C$390,335, or C$0.01 per share.
  • Moderate pointGross margin rose to 29.8% from 8.6% in the second quarter.
  • Moderate pointTotal costs before grants and tax credits fell 22% sequentially to C$1.11 million.
  • Moderate pointRegulated testing revenue of C$363,112 rose 9% year over year and 13% sequentially.
  • Moderate pointATB Financial commitment accepted October 29 covers C$500,000 revolving operating and C$100,000 corporate credit card facilities.
6 minor points
  • Minor pointGeneral and administrative expenses declined 24% sequentially to C$413,276.
  • Minor pointCurrent ratio improved to 2.28 at September 30 from 2.07 at June 30.
  • Minor pointPreviously unbilled work was collected during the third quarter.
  • Minor pointEquipment sale-and-leaseback preserved cash by financing the company's mass spectrometry system.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Reduced cost base is expected to be more fully reflected in fourth-quarter results.
  • Minor pointGood Laboratory Practice certification preparations are progressing.

Negative

  • Minor pointEquipment sale-and-leaseback adds a lease financing obligation.

News Explained

Innovotech launched InnovoTEST hazardous-drug wipe kits in August and signed a November 3 agreement with Healthmark to bring them to hospital, community and long-term-care pharmacies across Canada, adding a named nationwide distribution channel.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Margins Improving, Liquidity Strengthened and Regulated Testing Revenue Growing

EDMONTON, Alberta – November 10, 2026 – TheNewswire – Innovotech Inc. (TSXV: IOT; OTCQB: IOTCF) (“Innovotech” or the “Company”), a life sciences services and technology company focused on applied microbiology, analytical chemistry, and regulated laboratory services, today reported its financial results for the three and nine months ended September 30, 2026. All amounts are in Canadian dollars.

The third quarter reflected the actions the Company took earlier in the year to align its cost structure with a lower revenue outlook for 2026. Revenue held steady at $661,762, the Company’s cost base came down significantly, and its net loss narrowed by 40% from the second quarter to $390,335, or $0.01 per share. The improvement built through the quarter as further changes took effect, with a net loss of approximately $24,000 in September.

Gross margin improved to 29.8% from 8.6% in the second quarter. Margins remain below what the Company believes the business can achieve, but they are moving in the right direction. Total costs before grants and tax credits fell 22% from the second quarter to $1.11 million, and general and administrative expenses decreased 24% to $413,276. As revenue grows on this leaner base, the Company expects margins to continue to recover.

Innovotech’s GMP, analytical chemistry and stability testing services had their strongest quarter of 2026, with revenue of $363,112, up 9% from the third quarter of 2025 and 13% from the second quarter. These services now represent more than half of the Company’s revenue and are built on recurring work for a broad base of pharmaceutical, biotechnology, healthcare and industrial clients. The growth reflects consistent, strong customer service and the capabilities the Company has invested in, including additional equipment and clean room capacity for GMP-associated sterility testing.

The Company also strengthened its financial position. Working capital was $712,523 at September 30, 2026, and its current ratio improved to 2.28 from 2.07 on June 30. During the quarter, the Company collected previously unbilled work, financed its MALDI-TOF mass spectrometry system through a sale-and-leaseback that preserved cash, and maintained tight control of expenses and receivables. On October 29, 2026, the Company accepted a commitment letter from ATB Financial for a $500,000 revolving operating facility and a $100,000 corporate credit card facility, and is consolidating its banking with ATB to simplify operations and reduce costs. These steps give the Company added flexibility to manage its cash flows and support its growth initiatives.

“We have taken the steps needed to keep Innovotech on firm footing,” said Craig Milne, CEO. “Our costs are down, our margins are recovering, and our regulated testing business is growing. I am proud of how our team has responded. They adapted quickly, stayed focused on our clients and delivered through a challenging year. There is more work to do, particularly on margins, but our key measures are moving in the right direction. We have a clear plan, and we are executing it.”

The Company is also building new sources of revenue. In August, Innovotech launched InnovoTEST™ hazardous drug wipe testing kits for pharmacies, hospitals and cancer centres, and on November 3, 2026, it signed a distribution agreement with Healthmark, a coast-to-coast Canadian distributor, to bring InnovoTEST™ to hospital, community and long-term care pharmacies across Canada. In contract research, the Company has begun introducing assay services using porcine skin explants, and its preparations toward Good Laboratory Practice (GLP) certification are progressing.

Because the Company continued to make changes through September, its third-quarter results do not yet reflect a full quarter of its reduced cost base. The Company expects the benefit to be more fully reflected in the fourth quarter and remains focused on returning to profitability by growing revenue across its regulated testing services and InnovoTEST™ on a leaner, more efficient platform.

The Company’s unaudited interim consolidated financial statements and MD&A for the three and nine months ended September 30, 2026 are available on SEDAR+ at www.sedarplus.ca and at www.innovotech.ca.

About Innovotech

Innovotech Inc. is a leading life sciences services and technology company specializing in contract research, analytical, and microbial testing within regulated healthcare markets. The Company is a recognized leader in biofilm science and antimicrobial testing and provides advanced laboratory services supporting medical device, pharmaceutical, and industrial product development. Innovotech combines deep scientific expertise with proprietary methodologies and products, including its widely used MBEC Assay® platform for high-throughput antimicrobial and antibiotic testing. Operating through ISO-certified and GMP-accredited laboratories, Innovotech supports clients across multiple sectors and geographies, delivering reliable, decision-enabling data aligned with regulatory expectations such as those of the U.S. Food and Drug Administration and Health Canada. Learn more at https://www.innovotech.ca.

Craig Milne, CEO

Innovotech Inc.

+1-604-239-1819

craig.milne@innovotech.ca

 

This document may contain forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements. Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; the Company’s reliance on a small number of customers including government organizations; fluctuations in operating results; government policies or actions; progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual property protection and potential costs associated with its defense; the Company’s exposure to lawsuits and other matters beyond the control of management. Should known or unknown risks or uncertainties materialize, or should management’s assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly make or update any forward- looking statements, except as required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

###

Copyright (c) 2026 TheNewswire - All rights reserved.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were Innovotech's third-quarter 2026 earnings results?

Innovotech reported a C$390,335 net loss, or C$0.01 per share, on revenue of C$661,762 for the three months ended September 30, 2026. The net loss narrowed 40% from the second quarter, while gross margin increased to 29.8% from 8.6%.

How much did Innovotech's regulated testing revenue grow in the third quarter of 2026?

Revenue from good manufacturing practice (GMP), analytical chemistry and stability testing services reached C$363,112, up 9% from the third quarter of 2025 and 13% from the second quarter of 2026. These services represented more than half of company revenue.

Why does Innovotech expect more cost savings to show in fourth-quarter 2026 results?

Innovotech expects its reduced cost base to be more fully reflected in the fourth quarter because changes continued through September. Third-quarter results therefore did not include a full quarter of the reduced cost base. The net loss in September was approximately C$24,000.

Keep reading